biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by JDavenporton Dec 20, 2022 5:02pm

208 Views

Post# 35183275

It's snowing, hard!

Bioasis has just posted 16 material change and material contracts documents on SEDAR.

This is the fine print and it's not a simple as pof makes it out to be. It begins to answer the questions I have asked over the last few days, some of which I have been asking for years.. My guess is that cross-linkages between these contracts are near impossible to decypher.

I'm posting this because it alarming.

Stockhouse is processing the deactivation of my alias. I confirmed this morning my desire to have it deactivated.

I did not watch or listen to the Webinar.

jd

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages